Personalized cell therapy for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a personalized treatment for non-small cell lung cancer that uses a patient's own immune cells to fight the tumor. It may help patients with early or advanced stages of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have non-small cell lung cancer, at any stage (I, II, or III).
- You need to have enough tumor tissue for analysis.
- You must be able to attend follow-up visits and give blood samples.
- You should not have an active infection or conditions that make blood or tissue sampling unsafe.
- You should not have had another cancer in the past that could affect the trial results.
- You should not be taking immunosuppressive drugs like high-dose steroids.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
This trial is testing a personalized approach to combining chemotherapy and immunotherapy for people with advanced non-small-cell lung cancer that doesn't have certain gene changes. The goal is to find the most effective treatment plan based on your immune system's response.
This trial uses real-world data to study how to personalize treatment for advanced non-small cell lung cancer. It looks at medical records from 2011 to 2024 to find the best therapy approaches.
This trial tests a personalized treatment using your own immune cells (T cells) that are specially trained to find and attack lung cancer cells. It may help people with advanced or relapsed lung cancer who have not improved with standard treatments.
This trial tests if a personalized treatment plan, guided by a blood test for tumor DNA, can improve outcomes for people with untreated, surgically removable lung cancer. It combines chemotherapy with immunotherapy before surgery.
This trial tests a personalized mRNA vaccine (made from your own tumor's genetic fingerprint) combined with an immunotherapy drug called adebrelimab. The goal is to see if this combination can help prevent lung cancer from coming back or slow its growth.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.